deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 1-arm NCT01970722

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Optional Postoperative Normothermic Intraperitoneal (IP) Chemotherapy to Treat Primary or Recurrent Carcinoma of Ovarian, Fallopian Tube, Uterine, or Peritoneal Origin

Sponsor: City of Hope Medical Center

Conditions FIGO Stage IVA Ovarian Cancer FIGO Stage IVB Ovarian Cancer Platinum-Resistant Ovarian Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Recurrent Uterine Corpus Carcinoma Stage III Fallopian Tube Cancer AJCC v7 Stage III Ovarian Cancer AJCC v6 and v7 Stage III Primary Peritoneal Cancer AJCC v7 Stage III Uterine Corpus Cancer AJCC v7 Stage IIIA Fallopian Tube Cancer AJCC v7 Stage IIIA Ovarian Cancer AJCC v6 and v7 Stage IIIA Primary Peritoneal Cancer AJCC v7 Stage IIIA Uterine Corpus Cancer AJCC v7 Stage IIIB Fallopian Tube Cancer AJCC v7 Stage IIIB Ovarian Cancer AJCC v6 and v7 Stage IIIB Primary Peritoneal Cancer AJCC v7 Stage IIIB Uterine Corpus Cancer AJCC v7 Stage IIIC Fallopian Tube Cancer AJCC v7 Stage IIIC Ovarian Cancer AJCC v6 and v7 Stage IIIC Primary Peritoneal Cancer AJCC v7 Stage IIIC Uterine Corpus Cancer AJCC v7 Stage IV Fallopian Tube Cancer AJCC v6 and v7 Stage IV Ovarian Cancer AJCC v6 and v7 Stage IV Primary Peritoneal Cancer AJCC v7 Stage IV Uterine Corpus Cancer AJCC v7 Stage IVA Uterine Corpus Cancer AJCC v7 Stage IVB Uterine Corpus Cancer AJCC v7
Interventions Carboplatin Cisplatin Gemcitabine Hydrochloride Laboratory Biomarker Analysis Paclitaxel Pegylated Liposomal Doxorubicin Hydrochloride Quality-of-Life Assessment Therapeutic Conventional Surgery
Updated 20 times since 2017 Last updated: Mar 3, 2026 Started: May 19, 2014 Primary completion: Jan 5, 2027 Completion: Jan 5, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on FIGO Stage IVA Ovarian Cancer and FIGO Stage IVB Ovarian Cancer, this trial is ongoing. The trial is conducted by City of Hope Medical Center and has accumulated 20 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshot~Sep 2017 – ~Nov 2017 · 2 months · monthly snapshot~Nov 2017 – ~Mar 2018 · 4 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Nov 2019 · 12 months · monthly snapshot~Nov 2019 – ~Mar 2020 · 4 months · monthly snapshot~Mar 2020 – ~Aug 2020 · 5 months · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jul 2022 · 10 months · monthly snapshot~Jul 2022 – ~Apr 2023 · 9 months · monthly snapshot~Apr 2023 – ~May 2024 · 13 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – ~Mar 2026 · 10 months · monthly snapshot~Mar 2026 – present · 4 months · monthly snapshot

Change History

20 versions recorded

  1. Mar 2026 — Present [monthly]

    Active Not Recruiting PHASE1

  2. May 2025 — Mar 2026 [monthly]

    Active Not Recruiting PHASE1

  3. Sep 2024 — May 2025 [monthly]

    Active Not Recruiting PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  5. May 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 15 earlier versions

  1. Apr 2023 — May 2024 [monthly]

    Active Not Recruiting PHASE1

  2. Jul 2022 — Apr 2023 [monthly]

    Active Not Recruiting PHASE1

  3. Sep 2021 — Jul 2022 [monthly]

    Active Not Recruiting PHASE1

  4. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1

  5. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  6. Aug 2020 — Oct 2020 [monthly]

    Recruiting PHASE1

  7. Mar 2020 — Aug 2020 [monthly]

    Recruiting PHASE1

  8. Nov 2019 — Mar 2020 [monthly]

    Recruiting PHASE1

  9. Nov 2018 — Nov 2019 [monthly]

    Recruiting PHASE1

  10. Jun 2018 — Nov 2018 [monthly]

    Recruiting PHASE1

  11. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

    Phase: NA → PHASE1

  12. Nov 2017 — Mar 2018 [monthly]

    Recruiting NA

  13. Sep 2017 — Nov 2017 [monthly]

    Recruiting NA

  14. Feb 2017 — Sep 2017 [monthly]

    Recruiting NA

  15. Jan 2017 — Feb 2017 [monthly]

    Recruiting NA

    First recorded

May 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • City of Hope Medical Center
  • National Cancer Institute (NCI)
Data source: City of Hope Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations